Gabather AB (publ) (STO:GABA)
Sweden
· Delayed Price · Currency is SEK 0.0454
+0.0010 (2.25%)
Mar 9, 2026, 5:29 PM CET
Gabather AB Company Description
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases.
The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer’s disease.
It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer’s disease, schizophrenia, and major depressive disorders.
The company was incorporated in 2014 and is based in Södertälje, Sweden.
Gabather AB (publ)
| Country | Sweden |
| Founded | 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Michael-Robin Witt |
Contact Details
Address: Forskargatan 20J Södertälje, 151 36 Sweden | |
| Phone | 46 7 36 87 28 39 |
| Website | gabather.com |
Stock Details
| Ticker Symbol | GABA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0010869552 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael-Robin Witt | Chief Executive Officer, CSO and Director |
| Dr. Christine Ryan | Chief Operating Officer |